國家衛生研究院 NHRI:Item 3990099045/9412
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 924973      線上人數 : 949
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/9412


    題名: Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes
    作者: Tseng, CH
    貢獻者: National Institute of Environmental Health Sciences
    摘要: BACKGROUND: The risk of pancreatic cancer associated with incretin-based therapies is controversial. METHODS: This study retrospectively analyzed the National Health Insurance database including patients with newly diagnosed type 2 diabetes mellitus at an age >/=25 years between 1999 and 2010. A total of 71,137 ever users of sitagliptin and 933,046 never users were followed for pancreatic cancer until December 31, 2011. A time-dependent approach was used to calculate incidence and estimate hazard ratios adjusted for propensity score using Cox regression. RESULTS: During follow-up, 83 ever users and 3,658 never users developed pancreatic cancer, representing an incidence of 73.6 and 55.0 per 100,000 person-years, respectively. The adjusted hazard ratio (95% confidence intervals) for ever versus never users was 1.40 (1.13-1.75). The respective adjusted hazard ratio for the first, second, and third tertile of cumulative dose <14,700, 14,700-33,700 and >33,700 mg was 1.83 (1.28-2.62), 1.97 (1.41-2.76) and 0.72 (0.45-1.15). For average daily dose of <50, 50-99.9 and >/=100 mg, the respective hazard ratio was 3.10 (1.17-8.26), 1.01 (0.63-1.61) and 1.53 (1.18-1.97). CONCLUSIONS: Sitagliptin is significantly associated with a higher risk of pancreatic cancer, especially when the cumulative dose is <33,700 mg. The risk diminished in users with a higher cumulative dose. The daily dose of sitagliptin should better be kept <100 mg and its use should be reconsidered in patients who suffer from severe renal impairment and thus a daily dose of <50 mg is always recommended. Future studies are required to confirm the findings with more appropriate adjustment for smoking.
    日期: 2016-01
    關聯: European Journal of Clinical Investigation. 2016 Jan;46(1):70-79.
    Link to: http://dx.doi.org/10.1111/eci.12570
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0014-2972&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000367930500008
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84955214680
    顯示於類別:[其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB26584246.pdf133KbAdobe PDF350檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋